Adma Biologics reported $136.02M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 136.02M 2.13M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 191.46M 36.9M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Takeda JPY 460.98B 134.07B Jun/2026